Hepatitis B Core-Related Antigen Point-of-Care Tests as a Risk Stratification Tool for Treatment Eligibility: Experience From Kenya - Top-Institutions - MDSpire

Hepatitis B Core-Related Antigen Point-of-Care Tests as a Risk Stratification Tool for Treatment Eligibility: Experience From Kenya

  • By

  • Louise O Downs

  • Dorcas Okanda

  • Oscar Chirro

  • Mwanakombo Zaharani

  • Benson Safari

  • Nadia Aliyan

  • Monique I Andersson

  • Yasuhito Tanaka

  • Anthony O Etyang

  • Yusuke Shimakawa

  • George Githinji

  • Philippa C Matthews

  • March 6, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    University of Oxford
    University of Oxford

    Oxford, Oxfordshire

    Key Differentiators

    • Hepatology
    • Infectious Diseases
    • Global Health

  • #2

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, Georgia

    Key Differentiators

    • Infectious Diseases
    • Public Health
    • Virology

  • #3

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, Maryland

    Key Differentiators

    • Immunology
    • Virology
    • Hepatology

  • #4

    University of Cape Town
    University of Cape Town

    Cape Town, Western Cape

    Key Differentiators

    • Hepatology
    • Infectious Diseases
    • Global Health

  • #5

    Imperial College London
    Imperial College London

    London, Greater London

    Key Differentiators

    • Hepatology
    • Global Health
    • Infectious Diseases

Original Source(s)

Hepatitis B Core-Related Antigen Point-of-Care Tests as a Risk Stratification Tool for Treatment Eligibility: Experience From Kenya

  • by Louise O Downs, Dorcas Okanda, Oscar Chirro, Mwanakombo Zaharani, Benson Safari, Nadia Aliyan, Monique I Andersson, Yasuhito Tanaka, Anthony O Etyang, Yusuke Shimakawa, George Githinji, Philippa C Matthews

  • March 6, 2025

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Hidden Gut Factor in Liver Disease

Healthy microbiome linked to reduced liver injury from Vibrio infection

  • May 8, 2026

  • 3 min
Bariatric Surgery and Risk of End-Stage Liver Disease in a Four-Country Cohort Study